Business
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the
About this update from Editas Medicine, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas’ drug discovery team and activities related to Editas Medicine’s pipeline of experimental medicines across all therapeutic areas and indications. “Earlier this year, we shared our vision to be a leader in programable in vivo gene editing, and I couldn’t be happier that Linda is joining Editas to help make this vision a reality. Linda has an outstanding track record of inventing or contributing to the foundations of multiple approved medicines and late-stage clinical candidates. Specifically, during her career, she has invented or contributed to two approved medicines and one late-stage asset, and she has initiated or advanced projects along the pipeline, delivering multiple other candidates to development,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. “Linda’s deep scientific knowledge and her translational abilities make her an ideal leader for our drug discovery team and partner to our clinical organization, enabling us to strategically develop and advance our pipeline to the clinic.” “With our new strategy and target selection criteria, we have a distinctive opportunity to build the Editas pipeline with a focus on gene editing medicines that will substantially differentiate from the current standard of care for serious diseases and ensure our targets maximize the probability of technical, regulatory, and commercial success. I am eager to lead the incredible team of scientists at Editas to reach this goal together for patients and all of our stakeholders,” said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. Dr. Burkly brings to Editas more than 35 years of experience in biotechnology as a research leader spanning the breadth of the drug discovery and development value chain. Her experience encompasses therapeutic areas of immunological, neurological, and rare genetic disorders. Linda also has a track record of contributing to the foundations of approved medicines and late-stage clinical candidates including Trogarzo®, Tysabri®, and Dapirolizumab (...